Skip to main content

Table 1 Retrospective studies of patients with EGFR ex20ins NSCLC treated with chemotherapy

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Treatment (reference) N Line ORR (%) mPFS (months) mOS (months)
Platinum-based chemotherapy [12] 105 1 19.2 6.4 NA
Platinum-based chemotherapy [13] 21 1 19.0 6.5 NA
Platinum-based chemotherapy [14] 49 1 NA 7.6 19.9
Pemetrexed-based chemotherapy [15] 77 1 41.6 5.5 25